Experiment 815487

Details

PropertyValue
Pharmacology
Administration routeIV INFUSION
OrganismMaytenus buchananii (CELASTRACEAE)
CitationEAGAN,RT: CREAGAN,ET: INGLE,JN: FRYTAK,S: RUBIN,J:. (1978). PHASE II EVALUATION OF MAYTANSINE IN PATIENTS WITH METASTATIC LUNG CANCER.. 62()
Amount utilized
Compound isolated
DiseasePHASE II CLINICAL TRIAL INVOLVING 47 EVALUABLE CANCER PATIENTS WITH ADVANCED LUNG CANCER OVERALL TUMOR REGRESSION WAS 8% CONCLUSION WAS THAT MORE FREQUENT TREATMENT WOULD BE MORE BENEFICIAL
Dose amount0.6 MG
Number1
Qualitative resultWEAK ACTIVITY
AnimalHUMAN ADULT
Per unitSQ M BODY SURFACE
Dose expressionDOSE
GenderGIVEN TO BOTH SEXES